Getting rid of refractory hemophilia.

In a prospective randomized, multicenter study of immune tolerance induction(ITI) in patients with hemophilia A refractory to replacement therapy after the development of alloantibodies that inhibit factor VIII (FVIII) activity, Hay and DiMichele compared two regimens, a low dose of FVIII (50 IU/Kg thrice weekly)or a high-dose (200 IU/kg daily

RCT Entities:   Population Interventions Outcomes